Advertisement

Topics

Finch Therapeutics Group Company Profile

06:52 EDT 15th August 2018 | BioPortfolio

Finch Therapeutics, a mission-driven microbiome engineering company, is developing novel microbial therapies to serve patients with serious and unmet medical needs. Founded by data scientists, clinicians, and microbiologists from MIT and OpenBiome, Finch uses machine- learning algorithms informed by high-throughput molecular data to reverse engineer successful clinical experience with fecal transplantation. Rather than relying on in-vitro screening of a library of microbes, Finch uses this human-first discovery approach to identify strains that drive clinical outcomes and to develop therapies that deliver these microbial communities to patients. FIN-524, a collection of microbes grown in pure culture to treat IBD, is Finch’s first product candidate based on a Rationally-Selected Microbiota™.


News Articles [1271 Associated News Articles listed on BioPortfolio]

Active-Investors: Research Reports on, Cronos Group, Antibe Therapeutics, Emerald Health Therapeutics, and BriaCell Therapeutics

LONDON, UK / ACCESSWIRE / February 16, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: Cronos Group, Antibe Th...

Juno Therapeutics Spinout Raises $90M

JW Therapeutics, a clinical stage biopharma company founded by Juno Therapeutics and WuXi AppTec Group, has closed a Series A financing worth $90 million.

Celularity raises $250mm in Series A round

Regenerative medicine start-up Celularity Inc. raised $250mm in Series A funding from Celgene, United Therapeutics, Sorrento Therapeutics, Human Longevity, Genting Group, the Dreyfus Family Office, Se...

SalvaRX sees 'substantial progress' as investees score patent protection

Drug development company SalvaRX Group offered a business update on Thursday, confirming significant progress for investees iOx Therapeutics and Intensity Therapeutics. iOsx Therapeutics, in which ...

Microbiotica to Present at Top Microbiome Conferences

Cambridge, UK, 22 May 2018 – Microbiotica, a leading player in microbiome-based therapeutics, announces that it will present at leading microbiome conferences throughout May and June. Mic...

Pawar Law Group: Esperion Therapeutics, Inc. Reminder: Pawar Law Reminds of Important July 6, 2018 Lead Plaintiff Deadline in Class Action- ESPR

NEW YORK, NY / ACCESSWIRE / June 5, 2018 / Pawar Law Group reminds shareholders who purchased shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) from February 22, 2017 through May 1, 2018, both d...

Summit Therapeutics plc: Director/PDMR Shareholding

Summit Therapeutics plc ('Summit', the 'Company', or the 'Group')Director / PDMR Share DealingOxford, UK, Cambridge, MA, US, 16 July - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), announces ...

vTv Therapeutics shares soar on licensing tie-up with Chinese group Newsoara Biopharma

Newsoara will develop vTv Therapeutics' HPP737 as a new treatment for chronic obstructive pulmonary disease

PubMed Articles [2199 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Group Influences on Engaging Self-Control: Children Delay Gratification and Value It More When Their In-Group Delays and Their Out-Group Doesn't.

Self-control emerges in a rich sociocultural context. Do group norms around self-control influence the degree to which children use it? We tested this possibility by assigning 3- to 5-year-old childre...

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Clinical Trials [3978 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [2888 Associated Companies listed on BioPortfolio]

Lava Therapeutics

Lava Therapeutics’ proprietary platform is focused on developing next generation γδ T cell engaging bispecific antibodies to treat cancer. Our first-in-class immuno-onc...

Xenova Group PLC

Xenova Group plc is an emerging pharmaceutical group, specialising in the development of new small molecule drugs. The company’s strategy is to develop commercially attractive new drugs, primarily i...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

More Information about "Finch Therapeutics Group" on BioPortfolio

We have published hundreds of Finch Therapeutics Group news stories on BioPortfolio along with dozens of Finch Therapeutics Group Clinical Trials and PubMed Articles about Finch Therapeutics Group for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Finch Therapeutics Group Companies in our database. You can also find out about relevant Finch Therapeutics Group Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Transplantation
Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...


Corporate Database Quicklinks



Searches Linking to this Company Record